The global polycystic kidney disease market accounted for USD 0.541 billion in 2023 and is expected to reach at USD 1.01 billion by 2034 with a CAGR of 5.82% during the forecast period 2024-2034. The rising incidence of kidney failure, advances in genetic research, increased awareness and screening programs, technological advances in imaging, regulatory incentives, and orphan drug designations will all fuel market expansion.
Advances in imaging technology, such as magnetic resonance imaging (MRI) and ultrasound, have improved PKD detection and monitoring. These imaging methods enable the visibility and characterization of kidney cysts, which aids in diagnosis, disease monitoring, and therapy planning. Imaging technology developments continue to improve PKD management and patient care. For instance, in December 2023, Otsuka reported good findings from a Phase 3 research of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
By type, the autosomal dominant PKD (ADPKD) segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the increased prevalence, greater awareness, and the availability of targeted therapies specifically designed to address the underlying genetic mechanisms of ADPKD. For instance, in September 2023, Pfizer announced the start of a Phase 2 trial for its investigational medication, PF-7191, to treat ADPKD. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of novel treatment options, expanding research and development activities, and increasing focus on addressing unmet needs in less common forms of polycystic kidney disease.
By treatment, the medication segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the growing demand for pharmacological interventions aimed at managing symptoms, slowing disease progression, and improving quality of life for patients with polycystic kidney disease. For instance, in August 2023, Novartis gained FDA approval for Tovok (tolvaptan) to treat ADPKD in children aged 2 to 5 years. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the emerging advancements in gene therapy technologies, promising preclinical and clinical trial results, and increasing investment in research and development for genetic-based treatments targeting polycystic kidney disease.
By diagnosis, the ultrasound segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the reliability, accessibility, and cost-effectiveness of ultrasound imaging for diagnosing and monitoring polycystic kidney disease, leading to widespread adoption across healthcare settings. For instance, in November 2023, Bayer reported favorable Phase 3 findings for finerenone in patients with chronic kidney disease (including ADPKD). Additionally, the MRI scan segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for higher-resolution imaging, improved accuracy in cyst detection and characterization, and expanding applications of MRI technology in diagnosing and monitoring polycystic kidney disease.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the convenience, patient preference, and widespread availability of oral medications for managing symptoms and slowing disease progression in polycystic kidney disease. For instance, in January 2024, Bristol Myers Squibb reported encouraging results from their Phase 2 trial of Orencia (abatacept) in ADPKD patients. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing development of injectable formulations offering improved bioavailability, faster onset of action, and better treatment outcomes for polycystic kidney disease.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the high patient volumes, advanced medical infrastructure, and comprehensive healthcare services offered by hospitals for the diagnosis, treatment, and management of polycystic kidney disease. For instance, in December 2023, Teva got FDA approval for their generic version of tolvaptan tablets to treat ADPKD. Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on personalized care, specialized expertise, and a multidisciplinary approach to managing polycystic kidney disease, driving patients' preference for specialty clinics.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, high prevalence of polycystic kidney disease, increasing adoption of novel treatments, and favorable reimbursement policies in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about polycystic kidney disease, improving healthcare infrastructure, increasing disposable income, and expanding access to healthcare services in the Asia Pacific region. For instance, in February 2024, AstraZeneca announced the start of a Phase 3 trial of anifrolumab in patients with lupus nephritis, a disease that can arise in PKD.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Advances in imaging technology, such as magnetic resonance imaging (MRI) and ultrasound, have improved PKD detection and monitoring. These imaging methods enable the visibility and characterization of kidney cysts, which aids in diagnosis, disease monitoring, and therapy planning. Imaging technology developments continue to improve PKD management and patient care. For instance, in December 2023, Otsuka reported good findings from a Phase 3 research of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
By type, the autosomal dominant PKD (ADPKD) segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the increased prevalence, greater awareness, and the availability of targeted therapies specifically designed to address the underlying genetic mechanisms of ADPKD. For instance, in September 2023, Pfizer announced the start of a Phase 2 trial for its investigational medication, PF-7191, to treat ADPKD. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of novel treatment options, expanding research and development activities, and increasing focus on addressing unmet needs in less common forms of polycystic kidney disease.
By treatment, the medication segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the growing demand for pharmacological interventions aimed at managing symptoms, slowing disease progression, and improving quality of life for patients with polycystic kidney disease. For instance, in August 2023, Novartis gained FDA approval for Tovok (tolvaptan) to treat ADPKD in children aged 2 to 5 years. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the emerging advancements in gene therapy technologies, promising preclinical and clinical trial results, and increasing investment in research and development for genetic-based treatments targeting polycystic kidney disease.
By diagnosis, the ultrasound segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the reliability, accessibility, and cost-effectiveness of ultrasound imaging for diagnosing and monitoring polycystic kidney disease, leading to widespread adoption across healthcare settings. For instance, in November 2023, Bayer reported favorable Phase 3 findings for finerenone in patients with chronic kidney disease (including ADPKD). Additionally, the MRI scan segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for higher-resolution imaging, improved accuracy in cyst detection and characterization, and expanding applications of MRI technology in diagnosing and monitoring polycystic kidney disease.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the convenience, patient preference, and widespread availability of oral medications for managing symptoms and slowing disease progression in polycystic kidney disease. For instance, in January 2024, Bristol Myers Squibb reported encouraging results from their Phase 2 trial of Orencia (abatacept) in ADPKD patients. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing development of injectable formulations offering improved bioavailability, faster onset of action, and better treatment outcomes for polycystic kidney disease.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global polycystic kidney disease market in 2023 owing to the high patient volumes, advanced medical infrastructure, and comprehensive healthcare services offered by hospitals for the diagnosis, treatment, and management of polycystic kidney disease. For instance, in December 2023, Teva got FDA approval for their generic version of tolvaptan tablets to treat ADPKD. Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on personalized care, specialized expertise, and a multidisciplinary approach to managing polycystic kidney disease, driving patients' preference for specialty clinics.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, high prevalence of polycystic kidney disease, increasing adoption of novel treatments, and favorable reimbursement policies in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about polycystic kidney disease, improving healthcare infrastructure, increasing disposable income, and expanding access to healthcare services in the Asia Pacific region. For instance, in February 2024, AstraZeneca announced the start of a Phase 3 trial of anifrolumab in patients with lupus nephritis, a disease that can arise in PKD.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Treatment, Diagnosis, Route of Administration, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Polycystic Kidney Disease Market Report 2023 - 2034
Polycystic Kidney Disease Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Autosomal Dominant Polycystic Kidney Disease
- Autosomal Recessive Polycystic Kidney Disease
- Others
Polycystic Kidney Disease Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Medication
- Surgery
- Others
Polycystic Kidney Disease Market Analysis & Forecast by Diagnosis 2023 - 2034 (Revenue USD Bn)
- Ultrasound
- CT Scan
- MRI Scan
Polycystic Kidney Disease Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Parenteral
- Others
Polycystic Kidney Disease Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospital
- Speciality Clinics
- Others
Polycystic Kidney Disease Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Polycystic Kidney Disease Market: Type Estimates & Trend Analysis
8. Polycystic Kidney Disease Market: Treatment Estimates & Trend Analysis
9. Polycystic Kidney Disease Market: Diagnosis Estimates & Trend Analysis
10. Polycystic Kidney Disease Market: Route of Administration Estimates & Trend Analysis
11. Polycystic Kidney Disease Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Polycystic Kidney Disease Market
14. Europe Global Polycystic Kidney Disease Market
15. Asia Pacific Global Polycystic Kidney Disease Market
16. Latin America Global Polycystic Kidney Disease Market
17. MEA Global Polycystic Kidney Disease Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Otsuka Pharmaceutical Co. Ltd.
- Sanofi S.A.
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Novartis International AG
- Bayer AG
- Bristol Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- AstraZeneca PLC
- Merck & Co. Inc.
- AbbVie Inc.
- Reata Pharmaceuticals Inc.
- Kadmon Holdings Inc.
- Vertex Pharmaceuticals Incorporated
- Ardelyx Inc.
